INDIVIDUALIZATION OF THERAPY WITH ALZHEIMER'S DISEASE AGENTS

Details for Australian Patent Application No. 2002312667 (hide)

Owner MCGILL UNIVERSITY

Inventors LEYLAND-JONES, Brian

Pub. Number AU-A-2002312667

PCT Number PCT/CA02/00838

PCT Pub. Number WO2002/099422

Priority 60/295,860 06.06.01 US

Filing date 6 June 2002

Wipo publication date 16 December 2002

International Classifications

G01N 033/53 Investigating or analysing materials by specific methods not covered by groups - Immunoassay

Event Publications

2 January 2003 Complete Application Filed

  Priority application(s): 60/295,860 06.06.01 US

8 May 2003 Application Open to Public Inspection

  Published as AU-A-2002312667

11 March 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002312668-TRICYCLIC TERPENES OF THE FAMILY OF ABIETIC ACID AS RANTES RECEPTOR LIGANDS

2002312666-ANTHER-SPECIFIC TAA1 GENES ENCODING FATTY ACYL CO-A REDUCTASES, AND USES THEREOF